Our Researchers


Dr Andrea Wise- Kidney Regeneration and Stem Cell Laboratory, Monash University

Kidney organoids from patients with Polycystic Kidney Disease

The reprogramming of adult cells to generate stem cells – namely, induced pluripotent stem cells – has advanced the study of disease modelling. Recently, there has been great excitement in the ability of iPSCs to self-assemble into three-dimensional structures that resemble mini-kidneys. These kidney organoids express markers of different kidney cell types and show great potential in many applications including disease modelling and regenerative medicine. This project will develop these “kidneys in a dish” targeted to PKD. This research will facilitate the use of kidney organoids from PKD patients, and genetically altered PKD organoids, for disease modelling, drug screening, and in the future, potential development of novel stem cell replacement therapies for this debilitating kidney disease for which there is no cure.


Dr Sayan Saravanabavan- Centre for Transplant and Renal Research, Westmead Institute for Medical Research, The University of Sydney

Role of mitochondrial genomic analysis as a prognostic biomarker in autosomal dominant polycystic kidney disease (ADPKD)

Genetic testing in ADPKD is in the early stages of development, and more sophistication is needed to help predict who is at higher risk of developing kidney failure. Energy metabolism in cells is altered in ADPKD and changes (mutations) in genes that regulate the mitochondria (the main energy producing organelle in our body which has its own genes) may worsen the severity of ADPKD. The aim of this study is to determine if mutations in mitochondrial genes affect the severity of ADPKD. The results of this study could help better identify patients who are at higher risk of developing kidney failure, and also lead to new approaches for treating ADPKD.


Dr Cara Hildreth- Department of Biomedical Sciences, Macquarie University

Is a hormone controlled by the brain driving high blood pressure in PKD?

It is well known that high blood pressure is common in people with polycystic kidney disease. Why blood pressure increases in people with polycystic kidney disease, however, is less well known. This project seeks to determine how the brain is contributing to the development of high blood pressure in polycystic kidney disease by uncovering what hormonal changes the brain is initiating that result in high blood pressure. This work has the potential to identify new treatment targets that could be used in individuals with polycystic kidney disease to lower blood pressure and reduce their risk of developing diseases associated with high blood pressure.


Assoc. Professor Andrew Mallett- Centre for Health Services Research, The University of Queensland, Australasian Kidney Trials Network

The IMPEDE-PKD Trial (Implementation of Metformin theraPy to Ease DEcline of kidney function in PKD).

There is an urgent need for treatments to slow the loss of kidney function and prevent complications in affected patients and families with ADPKD. Repurposing of existing medications is a promising way to potentially expedite this. Laboratory studies suggest Metformin, a common diabetes medication, might be one such medication.

The aim of this study is to establish a randomised clinical trial of Metformin amongst patients with ADPKD to investigate its potential to slow kidney function decline. Pre-clinical studies suggest that there are ADPKD disease pathways that can be advantageously modified by administration of Metformin. The common use of this medication, including in non-diabetic conditions such as polycystic ovarian syndrome, its relative inexpensive nature as well as its defined side effect and dosing profiles in kidney disease lend it to the conduct of a clinical trial to address this aim.  If successful, this would dramatically change the prognosis for many Australians living with this condition and hoping for a future in which dialysis can be avoided.

* This Project is funded in partnership with The BEAT-CKD Program

Professor Sharon Ricardo- Kidney Regeneration and Stem Cell Laboratory, Monash University

Clinical development of a monoclonal antibody-based therapeutic targeting polycystic kidney disease.

There are various supportive treatments that can be used to control the symptoms of PKD, to help prevent or slow down the loss of kidney function. However, there are currently no treatment options to prevent cysts developing or reverse the process once formed. As such, there is currently no cure for PKD, where the only options to treat kidney failure are dialysis or organ transplantation.

Our recent discovery has identified a novel protein, called WISP1, that may play an important role in the formation of kidney cysts and the detrimental scarring of the kidneys that leads to reduced kidney function over time. The successful completion of these studies will unravel the role that WISP1 plays in both cyst growth and kidney scarring. Moreover, we will develop a protein that inhibits WISP1 protein production that will be used therapeutically to retard cyst growth and slow or alleviate disease progression.


Dr Gopi Rangan- Centre for Transplant and Renal Research, Westmead Institute for Medical Research, The University of Sydney

Role of DNA damage signalling in Autosomal Dominant Polycystic Kidney Disease.

This project will determine if stopping damage to the genetic coding material (called DNA) reduces the formation of kidney cysts in polycystic kidney disease.


Professor John Shine- Molecular Genetics of Inherited Kidney Disorders, Garvan Institute of Medical Research, Sydney

Identifying novel mutational mechanisms in the genetic pathogenesis of PKD.

ADPKD is the most common genetic kidney disorder – it causes cysts to develop within the kidney, which eventually destroy the normal kidney tissue and lead to renal failure in many patients. Despite how common the disease is there are still many gaps in our understanding. In many families we still cannot identify the genetic cause of their disease and there remain questions about the reason kidney cysts develop and destroy the kidney. Our project will use the latest in genetic sequencing technologies, called Whole Genome Sequencing, to identify new genetic causes of ADPKD. Understanding new mechanisms will help in better understanding this complex disease and to develop ways to slow and treat ADPKD.

* This Project is funded in partnership with the PKD Foundation USA


Dr Amali Mallawaarachchi, Garvan Institute of Medical Research, Sydney

A novel genetic test for ADPKD – A new genetic sequencing technique which has shown promising results was previously trialled and now requires testing a larger study.

Partnering with the Mayo Clinic, this grant will work to test this with patients who have been sequenced by more established methods. It is anticipated that comparing the two methods will show the new test to be more detailed and accurate and to establish it as the lead genetic test for PKD in Australia. This will result in improvements for patients and assist with understanding underlying causes and to find a cure.

To read the final report please click here.


Professor Jacqueline Phillips, Macquarie University, Sydney

Genes and cellular stress in PKD- This grant will investigate how PKD genes can cause an increase in stress signals in kidney cells that drives cell damage and progression of kidney disease. 

These same processes can also be driven by the build-up of toxins in the blood that arises when kidney function declines and this project will further test if the combination of PKD mutation and toxins worsens the stress response in the cell. Determining how PKD leads to cell damage has the potential to change the way we treat patients from symptomatic to strategically targeted.


Dr Bo Wang, Monash University, Melbourne

The therapeutic potential of miRNA-based MAPK inhibition to slow the progression of PKD
Several therapeutic interventions have been designed specifically to inhibit cell proliferation in a variety of animal models of PKD. A cell signal–regulated kinase (MAPK) inhibitor is shown to effectively block cyst growth and kidney enlargement, and to preserve kidney function.

Recently, a unique microRNA was discovered that is important in regulation of gene expression and can slow down the over proliferation of kidney cells that lead to cyst formation. The project will investigate the mechanisms of microRNA in maintaining normal kidney cell function that will result in reduced cyst growth. The study will provide a novel target for PKD treatment with a high potential for clinical translation.


Dr Annette Wong, Westmead Institute for Medical Research, Sydney

Validation of copeptin as a prognostic molecular biomarker in patients with CKD stages 1 – 3 due to ADPKD- Predicting patients at high risk of kidney failure who therefore require medical follow-up is important however, currently there are no blood tests to provide this information.

Vasopressin is a natural hormone in the body that may cause kidney cysts to grow bigger. In the past it has been difficult to measure vasopressin but it can now can be measured easily using a test for copeptin. This project will determine if a simple blood and/or urine test for copeptin can help predict this risk in patients with early-stage ADPKD.